ReviewHematology. American Society of Hematology. Education Program2018
Drug-associated thrombocytopenia.
Review in Hematology. American Society of Hematology. Education Program, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 162 citations in OpenAlex.
- Antiepileptic drug therapy in companion animals: New perspectives on clinical pathology monitoring.Veterinary and animal science · 2026Review
- Real-time active surveillance for drug-induced Thrombocytopenia: A prospective interventional study.Exploratory research in clinical and social pharmacy · 2026Article
- Severe immune thrombocytopenia induced by vancomycin in a critically ill patient: a case report and literature review.Thrombosis journal · 2026Article
- Fulminant drug-induced immune thrombocytopenia in polycystic kidney disease with cyst infection.CEN case reports · 2026Article
- Ampicillin-dependent IgG Antibody Mediated Thrombocytopenia Confirmed Using Flow Cytometry.Internal medicine (Tokyo, Japan) · 2026Article
- Pharmacological Management of Thrombosis: Current State and Future Strategies.International journal of molecular sciences · 2026Review
- From Epistaxis to a Platelet Count of Four: A Rare Presentation of Teicoplanin-Induced Thrombocytopenia.Cureus · 2026Article
- Severe Postoperative Epistaxis Revealing Immune Thrombocytopenia: A Case Report.Journal of rhinology : official journal of the Korean Rhinologic Society · 2026Article
- Case report: A case of ITP-like thrombocytopenia induced by denosumab.Frontiers in pharmacology · 2026Article
- Prevalence, Risk Factors, Characteristics, and Clinical Outcomes of Thrombocytopenia in the Intensive Care Unit: A Prospective Single-Center Cohort Study.Critical care research and practice · 2026Article
- The Association Between Platelet Indices and Osteoarthritis: A Systematic Review and Meta-analysis.Clinical medicine insights. Arthritis and musculoskeletal disorders · 2026Article
- Cytopenias as Adverse Drug Reactions: A 10-Year Analysis of Reporting Structure, Rate, and Trend.Pharmaceuticals (Basel, Switzerland) · 2025Article
- In-hospital mortality prognostication for cancer patients with febrile neutropenia.Communications medicine · 2025Article
- Obinutuzumab-induced Acute Thrombocytopenia Mimicking Immune Thrombocytopenia in a Patient with Follicular Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- A Case of Piperacillin-Induced Immune Thrombocytopenia: Diagnostic Challenges and Management.Cureus · 2025Article
- Article
- Understanding Chemotherapy-Induced Thrombocytopenia: Implications for Gastrointestinal Cancer Treatment.Current oncology (Toronto, Ont.) · 2025Review
- Article
- Development and external validation of a machine learning model for predicting drug-induced immune thrombocytopenia in a real-world hospital cohort.BMC medical informatics and decision making · 2025Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many drugs have been implicated in drug-induced immune thrombocytopenia (DITP). Patients with DITP develop a drop in platelet count 5 to 10 days after drug administration with an increased risk of hemorrhage. The diagnosis of DITP is often challenging, because most hospitalized patients are taking multiple medications and have comorbidities that can also cause thrombocytopenia. Specialized laboratory diagnostic tests have been developed and are helpful to confirm the diagnosis. Treatment of DITP involves discontinuation of the offending drug. The platelet count usually starts to recover after 4 or 5 half-lives of the responsible drug or drug metabolite. High doses of intravenous immunoglobulin can be given to patients with severe thrombocytopenia and bleeding. Although in most cases, DITP is associated with bleeding, life-threatening thromboembolic complications are common in patients with heparin-induced thrombocytopenia (HIT). Binding of antiplatelet factor 4/heparin antibodies to Fc receptors on platelets and monocytes causes intravascular cellular activation, leading to an intensely prothrombotic state in HIT. The clinical symptoms include a decrease in platelet counts by >50% and/or new thromboembolic complications. Two approaches can help to confirm or rule out HIT: assessment of the clinical presentation using scoring systems and in vitro demonstration of antiplatelet factor 4/heparin antibodies. The cornerstone of HIT management is immediate discontinuation of heparin when the disease is suspected and anticoagulation using nonheparin anticoagulant. In this review, we will provide an update on the pathophysiology, diagnosis, and management of both DITP and HIT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.